Pacira BioSciences, Inc.PCRXNASDAQ
Loading
Revenue Growth AcceleratingAccelerating
Percentile Rank72
3Y CAGR+53.4%
5Y CAGR-3.4%
Year-over-Year Change
Year-over-year revenue growth rate
3Y CAGR
+53.4%/yr
vs +9.0%/yr prior
5Y CAGR
-3.4%/yr
Recent acceleration
Acceleration
+44.4pp
Accelerating
Percentile
P72
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 9.67% |
| Q3 2025 | -0.87% |
| Q2 2025 | 7.21% |
| Q1 2025 | -9.79% |
| Q4 2024 | 11.08% |
| Q3 2024 | -5.31% |
| Q2 2024 | 6.53% |
| Q1 2024 | -7.79% |
| Q4 2023 | 10.56% |
| Q3 2023 | -3.27% |
| Q2 2023 | 5.69% |
| Q1 2023 | -6.75% |
| Q4 2022 | 2.68% |
| Q3 2022 | -1.15% |
| Q2 2022 | 7.23% |
| Q1 2022 | -0.76% |
| Q4 2021 | 24.64% |
| Q3 2021 | -5.80% |
| Q2 2021 | 13.92% |
| Q1 2021 | -9.12% |
| Q4 2020 | 11.48% |
| Q3 2020 | 55.60% |
| Q2 2020 | -28.56% |
| Q1 2020 | -13.67% |
| Q4 2019 | 16.95% |
| Q3 2019 | 2.03% |
| Q2 2019 | 12.37% |
| Q1 2019 | -4.00% |
| Q4 2018 | 13.98% |
| Q3 2018 | -0.78% |
| Q2 2018 | 12.73% |
| Q1 2018 | -5.65% |
| Q4 2017 | 17.44% |
| Q3 2017 | -5.07% |
| Q2 2017 | 2.38% |
| Q1 2017 | -4.96% |
| Q4 2016 | 6.65% |
| Q3 2016 | -1.85% |
| Q2 2016 | 6.36% |
| Q1 2016 | -5.55% |